Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil Use Suggests Need For PDUFA Post-Market Provisions, Senator Says

Executive Summary

The use of Merck's human papilloma virus vaccine Gardasil in girls as young as nine years old underscores the need to apply FDA user fee funds to post-marketing surveillance of products, Sen. Barbara Mikulski, D-Md., said during a Senate Health Committee hearing March 14

You may also be interested in...



Rx Safety Bill Would Require Renegotiation Of User Fees, FDA Tells Senate

An expansion of FDA's drug safety authorities as envisioned by legislation from Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., would require a renegotiation of user fees with industry, Commissioner Andrew von Eschenbach said

Rx Safety Bill Would Require Renegotiation Of User Fees, FDA Tells Senate

An expansion of FDA's drug safety authorities as envisioned by legislation from Sens. Ted Kennedy, D-Mass., and Michael Enzi, R-Wyo., would require a renegotiation of user fees with industry, Commissioner Andrew von Eschenbach said

Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP

Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said

Related Content

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel